Hudson Bay Capital Management LP Invests $2.81 Million in Repligen Corporation $RGEN

Hudson Bay Capital Management LP bought a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,003 shares of the biotechnology company’s stock, valued at approximately $2,807,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the 3rd quarter valued at about $29,000. CWM LLC grew its holdings in Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares during the period. Johnson Financial Group Inc. purchased a new position in Repligen during the third quarter valued at approximately $65,000. Trust Co. of Vermont purchased a new position in Repligen during the third quarter valued at approximately $67,000. Finally, Wilmington Savings Fund Society FSB lifted its holdings in Repligen by 2,750.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 495 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Down 3.2%

Shares of RGEN opened at $113.88 on Friday. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $175.77. The stock has a market cap of $6.41 billion, a PE ratio of 133.98, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. The firm’s fifty day moving average is $140.22 and its two-hundred day moving average is $146.69. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same quarter in the prior year, the firm earned $0.44 EPS. Repligen’s quarterly revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on RGEN. Barclays lowered their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wells Fargo & Company lowered their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.